[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Park SJ, Kim YH: Percutaneous coronary intervention for unprotected left main coronary artery stenosis. Cardiol Clin; 2010 Feb;28(1):81-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous coronary intervention for unprotected left main coronary artery stenosis.
  • Because of the long-term benefit of coronary artery bypass graft (CABG) surgery in medical therapy, CABG has been the standard treatment of unprotected left main coronary artery (LMCA) stenosis.
  • However, with the advancement of techniques and equipment, the percutaneous interventional approach for implantation of coronary stents has been shown to be feasible for patients with unprotected LMCA stenosis.
  • The recent introduction of drug-eluting stents (DESs), together with advances in periprocedural and postprocedural adjunctive pharmacotherapies, has improved outcomes of percutaneous coronary interventions (PCIs) for these complex coronary lesions.
  • This review evaluates the current outcomes of PCI with DES in research conducted in several countries.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Coronary Stenosis / therapy
  • [MeSH-minor] Drug-Eluting Stents. Humans. Patient Selection. Prognosis

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19962051.001).
  • [ISSN] 1558-2264
  • [Journal-full-title] Cardiology clinics
  • [ISO-abbreviation] Cardiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 69
  •  go-up   go-down


2. Chieffo A, Park SJ, Meliga E, Sheiban I, Lee MS, Latib A, Kim YH, Valgimigli M, Sillano D, Magni V, Biondi-Zoccai G, Montorfano M, Airoldi F, Rogacka R, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Sangiorgi GM, Tobis J, Serruys PW, Colombo A: Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J; 2008 Sep;29(17):2108-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry.
  • AIMS: To evaluate the occurrence of late and very late stent thrombosis (ST) following elective drug-eluting stent (DES) implantation in unprotected left main coronary artery (LMCA) stenosis in a large multicentre registry.
  • METHODS AND RESULTS: All 731 consecutive patients who had sirolimus- or paclitaxel-eluting stent electively implanted in de novo lesions on unprotected LMCA in five centres were included.
  • Four (0.5%) patients had a definite ST: three early (two acute and one subacute) and one late ST, no cases of very late definite ST were recorded.
  • Therefore, 7/731 (0.95%) patients had a definite or a probable ST and all were on dual antiplatelet therapy at the time of the event.
  • CONCLUSION: Elective treatment of LMCA stenosis with DES appears safe with a 0.9% incidence of definite and probable ST at 29.5 ± 13.7 months.
  • [MeSH-major] Coronary Restenosis / prevention & control. Drug-Eluting Stents. Graft Occlusion, Vascular / etiology. Paclitaxel / administration & dosage. Sirolimus / administration & dosage. Tubulin Modulators / administration & dosage
  • [MeSH-minor] Aged. Female. Hospitalization. Humans. Male. Middle Aged. Myocardial Revascularization / methods. Registries. Treatment Outcome

  • Genetic Alliance. consumer health - Thrombosis.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Heart J. 2008 Sep;29(17):2064-6 [18664463.001]
  • (PMID = 18565967.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


3. Van Mieghem CA, Cademartiri F, Mollet NR, Malagutti P, Valgimigli M, Meijboom WB, Pugliese F, McFadden EP, Ligthart J, Runza G, Bruining N, Smits PC, Regar E, van der Giessen WJ, Sianos G, van Domburg R, de Jaegere P, Krestin GP, Serruys PW, de Feyter PJ: Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. Circulation; 2006 Aug 15;114(7):645-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound.
  • BACKGROUND: Surveillance conventional coronary angiography (CCA) is recommended 2 to 6 months after stent-supported left main coronary artery (LMCA) percutaneous coronary intervention due to the unpredictable occurrence of in-stent restenosis (ISR), with its attendant risks.
  • Multislice computed tomography (MSCT) is a promising technique for noninvasive coronary evaluation.
  • We evaluated the diagnostic performance of high-resolution MSCT to detect ISR after stenting of the LMCA.
  • METHODS AND RESULTS: Seventy-four patients were prospectively identified from a consecutive patient population scheduled for follow-up CCA after LMCA stenting and underwent MSCT before CCA.
  • Overall, the accuracy of MSCT for detection of angiographic ISR was 93%.
  • The sensitivity, specificity, and positive and negative predictive values were 100%, 91%, 67%, and 100%, respectively.
  • When analysis was restricted to patients with stenting of the LMCA with or without extension into a single major side branch, accuracy was 98%.
  • When both branches of the LMCA bifurcation were stented, accuracy was 83%.
  • CONCLUSIONS: Current MSCT technology, in combination with optimal heart rate control, allows reliable noninvasive evaluation of selected patients after LMCA stenting.
  • MSCT is safe to exclude left main ISR and may therefore be an acceptable first-line alternative to CCA.
  • [MeSH-major] Coronary Angiography / methods. Coronary Restenosis / radiography. Myocardial Revascularization / methods. Stents. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adrenergic beta-Antagonists / pharmacology. Aged. Coronary Artery Disease / physiopathology. Coronary Artery Disease / therapy. Coronary Vessels / physiopathology. Coronary Vessels / ultrasonography. Female. Heart Rate / drug effects. Heart Rate / physiology. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Risk Factors. Sensitivity and Specificity. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Circulation. 2006 Aug 15;114(7):616-9 [16908783.001]
  • (PMID = 16894038.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists
  •  go-up   go-down


Advertisement
4. Nomura T, Nakagawa Y, Urakabe Y, Naito D, Enomoto S, Nishikawa S, Keira N, Matsubara H, Tatsumi T: Subacutely progressed extensive aortic dissection complicated with catheter-induced dissection in left main coronary artery. J Cardiol; 2009 Aug;54(1):128-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subacutely progressed extensive aortic dissection complicated with catheter-induced dissection in left main coronary artery.
  • A 64-year-old man complaining of resting angina underwent emergent coronary angiogram and significant stenosis in the mid-left anterior descending artery was discovered.
  • Although deployment of the drug-eluting Cypher stent relieved the stenosis, the guiding catheter accidentally induced coronary dissection in the left main coronary artery (LMCA).
  • 20 days later, although asymptomatic, extensive aortic dissection was detected from the coronary sinus of Valsalva to the femoral artery.
  • 64-Row multidetector computed tomography demonstrated that the dissection originated from the LMCA and retrogradely expanded to the aorta.
  • This type of dissection is a rare complication related to coronary intervention and even in such a clinical setting, asymptomatic delayed progression of retrograde aortic dissection has not previously been reported to our knowledge.
  • [MeSH-major] Aneurysm, Dissecting / complications. Aortic Aneurysm / complications. Cardiac Catheterization / adverse effects. Coronary Disease / etiology
  • [MeSH-minor] Coronary Stenosis / therapy. Dissection. Humans. Iatrogenic Disease. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632532.001).
  • [ISSN] 1876-4738
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Ma YH, Cheng WZ, Gong F, Ma AL, Yu QW, Zhang JY, Hu CY, Chen XH, Zhang DQ: Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses. World J Gastroenterol; 2008 Sep 14;14(34):5274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the potential role of active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance.
  • The experimental treatment was orally administered with ACML-55 or PBS, followed by the inoculation of colon cancer cell line CT26.
  • RESULTS: Our results showed, compared to PBS treated mice, ACML-55 treatment significantly delayed colon cancer development in colon cancer-bearing Balb/c mice in vivo.
  • Treatment with ACML-55 enhanced both Ag specific activation and proliferation of CD4+ and CD8+ T cells, and increased the number of tumor Ag specific CD8+ T cells.
  • Interestingly, ACML-55 treatment also showed increased cell number of NK, and gammadeltaT cells, indicating the role of ACML-55 in activation of innate lymphocytes.
  • CONCLUSION: Our results demonstrate that ACML-55 therapy can enhance function in immune surveillance in colon cancer-bearing mice through regulating both innate and adaptive immune responses.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Colonic Neoplasms / immunology. Colonic Neoplasms / prevention & control. Drugs, Chinese Herbal / pharmacology. Mistletoe. Plant Lectins / pharmacology
  • [MeSH-minor] Animals. CD4-Positive T-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. Cell Line, Tumor. Disease Models, Animal. Female. Immunity, Innate / drug effects. Interferon-gamma / biosynthesis. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Lymphocyte Activation / drug effects. Male. Mice. Mice, Inbred BALB C. Monitoring, Immunologic. Phytotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2002 Oct;60(4):640-4 [12385925.001]
  • [Cites] Nat Rev Immunol. 2002 May;2(5):336-45 [12033739.001]
  • [Cites] Urology. 2004 Feb;63(2):259-63 [14972467.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3151-6 [15457562.001]
  • [Cites] Oncology. 1986;43 Suppl 1:51-65 [2433654.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3646-51 [1692765.001]
  • [Cites] Cancer Lett. 1990 May 30;51(2):103-8 [2344587.001]
  • [Cites] Cancer Immunol Immunother. 1990;32(4):221-7 [2124513.001]
  • [Cites] Cancer Immunol Immunother. 1993;36(4):237-44 [8439987.001]
  • [Cites] Cancer Lett. 1996 Jan 19;99(1):59-72 [8564930.001]
  • [Cites] Immunol Lett. 1996 Sep;52(2-3):69-72 [8905398.001]
  • [Cites] Cancer Lett. 1996 Dec 3;109(1-2):33-8 [9020900.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8 Suppl 1:S33-7 [9179365.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8 Suppl 1:S39-42 [9179366.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8 Suppl 1:S53-5 [9179369.001]
  • [Cites] Arzneimittelforschung. 1997 Oct;47(10):1145-51 [9368710.001]
  • [Cites] Cell Mol Life Sci. 1999 Apr;55(4):679-82 [10357236.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1521-9 [15547686.001]
  • [Cites] Toxicology. 2005 Feb 1;207(1):105-16 [15590126.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):5783-9 [16237070.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2007 Jun;39(6):445-52 [17558450.001]
  • [Cites] World J Gastroenterol. 2007 May 28;13(20):2811-8 [17569116.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3056-64 [10706694.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1118-22 [11590434.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1566-71 [11823483.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109 [11900986.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):433-42 [12900519.001]
  • (PMID = 18785279.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Plant Lectins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2744057
  •  go-up   go-down


6. Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A, LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators: Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol; 2009 May 12;53(19):1760-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
  • OBJECTIVES: The aim of this trial was to compare the safety and efficacy of paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) for treatment of unprotected left main coronary artery (uLMCA) disease.
  • METHODS: In this randomized study, 607 patients with symptomatic coronary artery disease undergoing percutaneous coronary intervention for uLMCA were enrolled: 302 were assigned to receive a PES (Taxus, Boston Scientific, Natick, Massachusetts) and 305 assigned to receive a SES (Cypher, Cordis, Johnson & Johnson, New Brunswick, New Jersey).
  • The primary end point was the combined incidence of death, myocardial infarction, and target lesion revascularization (TLR) at 1 year.
  • The secondary end point was angiographic restenosis on the basis of the LMCA area analysis at follow-up angiography.
  • RESULTS: At 1 year the cumulative incidence of death, myocardial infarction, or TLR was 13.6% in the PES and 15.8% in the SES group (relative risk [RR]: 0.85, 95% confidence interval [CI]: 0.56 to 1.29, p = 0.44).
  • CONCLUSIONS: Implantation of either PES or SES in uLMCA lesions is safe and effective; both of these drug-eluting stents provide comparable clinical and angiographic outcomes. (Drug-Eluting-Stents for Unprotected Left Main Stem Disease [ISAR-LEFT-MAIN]; NCT00133237).
  • [MeSH-major] Coronary Artery Disease / drug therapy. Coronary Restenosis / drug therapy. Drug-Eluting Stents. Immunosuppressive Agents / therapeutic use. Paclitaxel / therapeutic use. Sirolimus / therapeutic use. Tubulin Modulators / therapeutic use
  • [MeSH-minor] Aged. Angioplasty, Balloon, Coronary. Confidence Intervals. Coronary Angiography. Female. Humans. Incidence. Male. Myocardial Infarction / drug therapy. Myocardial Infarction / therapy. Platelet Aggregation Inhibitors / therapeutic use. Risk. Ticlopidine / analogs & derivatives. Ticlopidine / therapeutic use

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Cardiol. 2009 May 12;53(19):1769-72 [19422983.001]
  • (PMID = 19422982.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00133237
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Platelet Aggregation Inhibitors; 0 / Tubulin Modulators; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


7. Rdzanek A, Pietrasik A, Kochman J, Wilczynska J, Opolski G: Acute coronary syndrome caused by left main coronary artery plaque rupture and thrombosis - resolution after pharmacological treatment. Int J Cardiol; 2007 May 2;117(3):e92-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute coronary syndrome caused by left main coronary artery plaque rupture and thrombosis - resolution after pharmacological treatment.
  • In coronary angiography a lesion in the left main coronary artery (LMCA) is found.
  • Intravascular ultrasound (IVUS) examination confirms the diagnosis of the ruptured plaque with the presence of thrombus.
  • Because of the well preserved lumen area a decision to continue intensive pharmacotherapy is made.
  • The article discusses different management strategies in patients with confirmed ruptured plaque in LMCA.
  • [MeSH-major] Angina, Unstable / drug therapy. Angina, Unstable / etiology. Coronary Artery Disease / complications. Myocardial Infarction / drug therapy. Myocardial Infarction / etiology. Thrombosis / complications
  • [MeSH-minor] Acute Disease. Aged. Humans. Male. Remission Induction. Rupture, Spontaneous. Syndrome


8. Lindsey JB, Brilakis ES, Banerjee S: Acute coronary syndrome due to extrinsic compression of the left main coronary artery in a patient with severe pulmonary hypertension: successful treatment with percutaneous coronary intervention. Cardiovasc Revasc Med; 2008 Jan-Mar;9(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute coronary syndrome due to extrinsic compression of the left main coronary artery in a patient with severe pulmonary hypertension: successful treatment with percutaneous coronary intervention.
  • A patient with severe pulmonary (arterial) hypertension (PH) presented with a non-ST segment elevation myocardial infarction and recurrent angina at rest.
  • Coronary angiography showed severe ostial left main coronary artery (LMCA) stenosis; coronary arteries were otherwise normal.
  • Intravascular ultrasonography (IVUS) showed deformation of the LMCA due to extrinsic compression from a markedly dilated main pulmonary artery, which was confirmed by cardiac computed tomography.
  • The LMCA was successfully stented using a paclitaxel-eluting stent resulting in complete resolution of angina.
  • Extrinsic compression of the LMCA should be considered in patients with severe PH and angina; IVUS may aid in the diagnosis.
  • Percutaneous stent implantation may be the preferred treatment in this high-risk group of patients.
  • [MeSH-major] Acute Coronary Syndrome / therapy. Angioplasty, Balloon, Coronary. Coronary Stenosis / therapy. Hypertension, Pulmonary / complications. Pulmonary Artery / pathology
  • [MeSH-minor] Angina Pectoris / etiology. Angina Pectoris / therapy. Cardiovascular Agents / administration & dosage. Coronary Angiography. Dilatation, Pathologic. Drug-Eluting Stents. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Platelet Aggregation Inhibitors / therapeutic use. Severity of Illness Index. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206638.001).
  • [ISSN] 1878-0938
  • [Journal-full-title] Cardiovascular revascularization medicine : including molecular interventions
  • [ISO-abbreviation] Cardiovasc Revasc Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 0 / Platelet Aggregation Inhibitors; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Safley AM, Sebastian S, Collins TS, Tirado CA, Stenzel TT, Gong JZ, Goodman BK: Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer; 2004 May;40(1):44-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
  • We report a case of BCR-ABL-negative atypical chronic myeloid leukemia (CML) with translocation t(4;22) (q12;q11.2) juxtaposing the breakpoint cluster region (BCR) and platelet-derived growth factor receptor-alpha (PDGFRA) genes.
  • The patient was a 57-year-old man with a history of stage IV diffuse large B-cell lymphoma, status post-6 cycles of combination chemotherapy in 1999, who presented in August 2002 with enlarged lymph nodes, anemia, and marked leukocytosis (50 x 10(9) g/dL) consistent with a myeloproliferative disorder (MPD).
  • A bone marrow biopsy showed granulocytic hyperplasia, neutrophilia, and mild eosinophilia.
  • Initial cytogenetic evaluation by interphase FISH for BCR-ABL, to rule out a translocation 9;22, showed a variant signal pattern consistent with rearrangement of BCR at 22q11.2, but not ABL at 9q34.
  • Analysis of the patient's cDNA by polymerase chain reaction (PCR) for BCR-ABL was negative.
  • PCR amplification and subsequent sequence analysis demonstrated an in-frame 5'-BCR/3'-PDGFRA fusion in the patient's cDNA.
  • However, although the incidence of MPD involving translocations of PDGFRB has been well established, to our knowledge there are only two previous reports describing a BCR-PDGFRA fusion gene, in 3 patients diagnosed with atypical CML.
  • Here, we report the molecular and cytogenetic characterization of a patient with BCR-PDGFRA-positive MPD who had a complete hematologic response after treatment with imatinib mesylate.
  • [MeSH-major] Chromosome Breakage / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 4 / genetics. Cytogenetic Analysis / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Protein-Tyrosine Kinases. Receptor, Platelet-Derived Growth Factor alpha / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Humans. Male. Middle Aged. Myeloproliferative Disorders / genetics. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcr. Reading Frames / genetics

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15034867.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.11.1 / BCR protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


10. Toms DR, Cannick L, Stuart RK, Jenrette JM, Terwiliger L: Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia. Jpn J Radiol; 2010 Jul;28(6):476-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia.
  • The phenomenon occurs in a number of disease states, notably in myelofibrosis, thalassemia, immune thrombocytopenic purpura, sickle cell anemia, polycythemia vera, and myelodysplastic syndrome.
  • Reported treatments include red blood cell transfusions, surgical excision, decompressive laminectomy in cases of cord compression, chemotherapy, and irradiation.
  • Radiation therapy is highly effective for treating hematopoietic tissue because such tissues are extremely radiosensitive.
  • Megavoltage helical tomotherapy is a technical advance in the delivery of radiation therapy, allowing more conformal and precise treatments.
  • The present case report describes a patient with the diagnosis of atypical chronic myeloid leukemia and myelofibrosis who subsequently developed EMH of the pericardium with effusion and tamponade.
  • The patient tolerated treatment well without acute adverse effects.
  • [MeSH-major] Heart Diseases / radiotherapy. Hematopoiesis, Extramedullary / radiation effects. Leukemia, Myeloid / complications. Pericardium / radiation effects. Tomography, Spiral Computed / methods


11. Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S: TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood; 2003 May 1;101(9):3658-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) have been implicated in antitumor immunity and therapy.
  • In the present study, we investigated the sensitivity of Philadelphia chromosome (Ph1)-positive leukemia cell lines to TRAIL- or FasL-induced cell death to explore the possible contribution of these molecules to immunotherapy against Ph1-positive leukemias.
  • TRAIL, but not FasL, effectively induced apoptotic cell death in most of 5 chronic myelogenous leukemia-derived and 7 acute leukemia-derived Ph1-positive cell lines.
  • Moreover, primary leukemia cells from Ph1-positive acute lymphoblastic leukemia patients were also sensitive to TRAIL, but not to FasL, depending on DR4/DR5 expression.
  • Fas-associated death domain protein (FADD) and caspase-8, components of death-inducing signaling complex (DISC), as well as FLIP (FLICE [Fas-associating protein with death domain-like interleukin-1-converting enzyme]/caspase-8 inhibitory protein), a negative regulator of caspase-8, were expressed ubiquitously in Ph1-positive leukemia cell lines irrespective of their differential sensitivities to TRAIL and FasL.
  • Notably, TRAIL could induce cell death in the Ph1-positive leukemia cell lines that were refractory to a BCR-ABL-specific tyrosine kinase inhibitor imatinib mesylate (STI571; Novartis Pharma, Basel, Switzerland).
  • These results suggested the potential utility of recombinant TRAIL as a novel therapeutic agent and the possible contribution of endogenously expressed TRAIL to immunotherapy against Ph1-positive leukemias.
  • [MeSH-major] Apoptosis / drug effects. Arabidopsis Proteins. Intracellular Signaling Peptides and Proteins. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Membrane Glycoproteins / pharmacology. Neoplastic Stem Cells / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Apoptosis Regulatory Proteins. Benzamides. CASP8 and FADD-Like Apoptosis Regulating Protein. Carrier Proteins / physiology. Caspase 1 / physiology. Death Domain Receptor Signaling Adaptor Proteins. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Enzyme Inhibitors / pharmacology. Fas Ligand Protein. Fatty Acid Desaturases / physiology. Fusion Proteins, bcr-abl / antagonists & inhibitors. Humans. Imatinib Mesylate. Leupeptins / pharmacology. NF-kappa B / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / physiology. Peptides / pharmacology. Piperazines / pharmacology. Pyrimidines / pharmacology. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / physiology. Recombinant Proteins / pharmacology. TNF-Related Apoptosis-Inducing Ligand. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / pathology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506034.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Apoptosis Regulatory Proteins; 0 / Arabidopsis Proteins; 0 / Benzamides; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Carrier Proteins; 0 / Death Domain Receptor Signaling Adaptor Proteins; 0 / Enzyme Inhibitors; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Intracellular Signaling Peptides and Proteins; 0 / Leupeptins; 0 / Membrane Glycoproteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Peptides; 0 / Piperazines; 0 / Pyrimidines; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / Recombinant Proteins; 0 / SN50 peptide; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 110044-82-1 / acetylleucyl-leucyl-norleucinal; 8A1O1M485B / Imatinib Mesylate; EC 1.14.19.- / Fatty Acid Desaturases; EC 1.14.99.- / Fad7 protein, Arabidopsis; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.22.36 / Caspase 1
  •  go-up   go-down


12. Park SJ, Park DW: Left main stenting: is it a different animal? EuroIntervention; 2010 Dec;6 Suppl J:J112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left main stenting: is it a different animal?
  • For several decades, coronary-artery bypass grafting (CABG) has been regarded as the treatment of choice for patients with unprotected left main coronary artery (LMCA) disease.
  • However, because of marked advancements in techniques of percutaneous coronary intervention (PCI) with stenting and CABG, as well as adjunctive pharmacologic therapy, a new evaluation and review of current indications for optimal revascularisation therapy for LMCA disease may be required to determine the standard of care for these patients.
  • The available current evidence suggests that the composite outcome of death, myocardial infarction and stroke is similar in patients with LMCA disease who are treated with PCI with stenting or CABG, the only difference was the rate of repeat revascularisation.
  • Although PCI can be performed successfully in most LMCA lesions, "high-risk" anatomic subsets, especially involving distal LMCA bifurcation lesions, continue to present unique technical challenges to interventional cardiologists, and, therefore, an integrated approach combing advanced devices, tailored techniques, adjunctive support of physiologic and morphologic evaluation, and adjunctive pharmacologic agents should be reinforced to improve clinical outcomes.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Stents
  • [MeSH-minor] Drug-Eluting Stents. Humans. Metals. Patient Selection. Prosthesis Design. Risk Assessment. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21930474.001).
  • [ISSN] 1969-6213
  • [Journal-full-title] EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • [ISO-abbreviation] EuroIntervention
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


13. Gotzmann M, Bojara W, Germing A, Mügge A, Laczkovics A, Thiessen C, Tannapfel A, Lindstaedt M: Differential diagnosis of non-atherosclerotic left main coronary artery stenosis. BMJ Case Rep; 2009;2009:bcr0820080776
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of non-atherosclerotic left main coronary artery stenosis.
  • A left main coronary artery (LMCA) stenosis without any atherosclerotic changes elsewhere in the coronary artery tree is a rare finding, and some uncommon reasons for luminal narrowing should be considered.
  • An unusual case of non-atherosclerotic LMCA stenosis is reported.A middle-aged patient presented with acute myocardial infarction.
  • An immediate coronary angiography was ordered and revealed a subtotal mid LMCA stenosis.
  • A drug-eluting stent was successfully implanted in the LMCA.Operative revascularisation was recommended.
  • Histopathological examination of the tumour revealed a poorly differentiated squamous cell carcinoma.Postoperatively, the patient was treated with chemotherapy (carboplatin and docetaxel).
  • Five years after the first admission to our hospital, the patient died as a result of ventricular fibrillation.The differential diagnosis of non-atherosclerotic LMCA stenoses is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Heart. 1997 Oct;78(4):419-20 [9404263.001]
  • [Cites] Int J Cardiol. 1997 Apr 18;59(2):209-11 [9158179.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):236-7 [12118767.001]
  • [Cites] Tex Heart Inst J. 2006;33(2):253-5 [16878640.001]
  • [Cites] Clin Cardiol. 1990 May;13(5):360-6 [2347127.001]
  • [Cites] J Rheumatol. 1990 May;17(5):708-11 [2359086.001]
  • [Cites] Circulation. 1983 May;67(5):1151-4 [6831677.001]
  • [Cites] Int J Cardiol. 1993 Sep;41(2):165-7 [8282441.001]
  • [Cites] Int J Cardiol. 1995 Sep;51(2):202-3 [8522418.001]
  • [Cites] Angiology. 1996 Mar;47(3):305-9 [8638877.001]
  • [Cites] Clin Cardiol. 1996 Jun;19(6):509-12 [8790958.001]
  • [Cites] Ann Thorac Surg. 1999 Jun;67(6):1789-91 [10391298.001]
  • [Cites] Ann Thorac Surg. 1999 Jun;67(6):1791-3 [10391299.001]
  • [Cites] Heart. 2000 Jan;83(1):91-3 [10618343.001]
  • [Cites] J Thorac Cardiovasc Surg. 1976 Jul;72(1):123-6 [1084447.001]
  • [Cites] Heart. 2000 Dec;84(6):E12 [11083756.001]
  • [Cites] J Invasive Cardiol. 2004 Feb;16(2):89-91 [14760201.001]
  • [Cites] Heart. 2004 Apr;90(4):e21 [15020539.001]
  • [Cites] Can J Cardiol. 2008 May;24(5):e30-2 [18464951.001]
  • (PMID = 21687045.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027375
  •  go-up   go-down


14. Han Y, Wang S, Jing Q, Li Y, Liu H, Ma Y, Wang Z, Wang D, Luan B, Wang G, Chen T: Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease. Am J Cardiol; 2009 Jan 15;103(2):194-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease.
  • The use of paclitaxel-eluting stents (PES) for the treatment of unprotected left main coronary artery (LMCA) disease is controversial.
  • Between January 2003 and December 2006, a total of 287 patients undergoing percutaneous coronary intervention for LMCA lesions were consecutively registered.
  • PES recipients had distal left main bifurcation lesions more frequently compared with BMS recipients (72 vs 42%, p<0.01).
  • In conclusion, PES implantation provides a safe, effective therapy for unprotected LMCA disease and decreases the risk of major adverse cardiac events compared with BMS at a mean follow-up of 35 months.
  • [MeSH-major] Coronary Artery Disease / therapy. Drug-Eluting Stents. Paclitaxel / administration & dosage. Stents. Tubulin Modulators / administration & dosage
  • [MeSH-minor] China / epidemiology. Coronary Angiography. Female. Humans. Male. Middle Aged. Registries. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121435.001).
  • [ISSN] 1879-1913
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Martínez-Ríos MA, Méndez-Ortíz A, Gaspar J, Barragán-García R, Fernández-de-la-Reguera G, González-Quesada CJ: Left main coronary artery stenosis treatment with two paclitaxel-eluting stents in a patient with cardiac allograft vasculopathy. Arch Cardiol Mex; 2008 Oct-Dec;78(4):407-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left main coronary artery stenosis treatment with two paclitaxel-eluting stents in a patient with cardiac allograft vasculopathy.
  • Cardiac transplantation is a well defined therapy for end stage heart failure.
  • After the first year of transplantation, allograft coronary artery disease (ACAD) is the second main cause of death.
  • Once ACAD has been established, treatments such as coronary angioplasty, coronary stenting, and coronary bypass are performed.
  • We present a case of successful stenting of the left main coronary artery (LMCA) in a patient with ACAD.
  • Coronary angiogram showed a severe stenosis in the proximal segment of the LMCA; we performed stenting with a paclitaxel-eluting stent (PES).
  • Six months after the procedure, the patient had an elective angiogram, where we discovered a new severe occlusion distally to the former stent; a second PES was implanted.
  • Our report suggests the efficacy of PES as ACAD treatment of the unprotected LMCA.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Coronary Stenosis / therapy. Drug-Eluting Stents. Heart Transplantation / adverse effects. Paclitaxel / administration & dosage
  • [MeSH-minor] Coronary Restenosis / therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205549.001).
  • [ISSN] 1405-9940
  • [Journal-full-title] Archivos de cardiología de México
  • [ISO-abbreviation] Arch Cardiol Mex
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Ng MK, Yeung AC: Left main coronary artery disease: is CABG still the gold standard? Rev Cardiovasc Med; 2005;6(4):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left main coronary artery disease: is CABG still the gold standard?
  • Severe stenosis of the left main coronary artery (LMCA) is a coronary artery-disease manifestation of critical prognostic importance.
  • As a consequence of the survival advantage conferred by coronary artery bypass grafting (CABG) over medical therapy, lesions in the LMCA have been considered a standard indication for CABG for nearly 3 decades.
  • Initial attempts to treat LMCA disease percutaneously by balloon angioplasty resulted in poor clinical outcomes, leading many to regard significant LMCA disease as a contraindication for percutaneous coronary intervention (PCI).
  • However, the development and refinement of coronary stenting over the last 15 years, followed by the recent introduction of drug-eluting stents, has fueled renewed interest in percutaneous treatment of LMCA disease.
  • Outcomes of recent studies using sirolimus- and/or paclitaxel-eluting stents for treatment of LMCA disease have yielded rates of in-hospital and 1-year mortality that compare favorably with those of surgery.
  • This article will review the natural history of LMCA disease, the outcomes of CABG for LMCA disease, and the history and recent developments regarding PCI for LMCA disease.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Artery Disease / therapy. Coronary Stenosis / therapy. Stents


17. Lichtman MA, Rowe JM: The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol; 2004 Apr;31(2):185-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of patient age to the pathobiology of the clonal myeloid diseases.
  • The incidence of the major clonal myeloid diseases, clonal cytopenias, acute, subacute (oligoblastic), and chronic myelogenous leukemia, polycythemia vera, thrombocythemia, and idiopathic myelofibrosis increases in a log-linear manner from young adulthood through advanced age.
  • In older patients, diseases requiring cytotoxic treatment are more difficult and less successful to manage because comorbid conditions and poor performance status are more prevalent, decreasing the tolerance to therapy and increasing the frequency of side effects.
  • This age effect is highlighted by the dramatically less favorable outcome in older than younger patients with acute myeloid leukemia with similar "favorable" cytogenetic changes.
  • In addition, in acute and subacute myeloid leukemia in older patients, the disease is intrinsically more resistant to therapy.
  • Overexpression of drug resistance genes and unfavorable genetic mutations are more prevalent in older patients and provide evidence that acute myeloid leukemia is often qualitatively different in these patients.
  • Although improved drug schedules have led to significant improvements in event-free survival in younger patients, these improvements have been far less evident in older patients.
  • New approaches, especially the development of drugs aimed at new targets, will be required to obtain a high frequency of long-term remissions in older patients.
  • Agents that reverse inherent cellular drug resistance, farnesyltransferase inhibitors, BCL-2 inhibitors, and FLT3 inhibitors are early examples of such approaches.
  • [MeSH-major] Leukemia, Myeloid

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15112149.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


18. Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M, Ottinger H, Elmaagacli AH: Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant; 2004 Dec;34(12):1047-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia.
  • Atypical chronic myeloid leukemia (aCML) occurs rarely and is associated with a poor prognosis when treated with conventional chemotherapy.
  • We evaluated the outcome of aCML after allogeneic hematopoietic stem cell transplantation (HSCT).
  • One patient who was transplanted in advanced disease with bone marrow from his twin brother relapsed 19 months post transplant.
  • Analysis of the leukocyte chimerism of peripheral white blood cells and bone marrow buffy coat cells by VNTR-polymerase chain reaction (PCR) and single-nucleotide polymorphism real-time PCR revealed complete chimerism in all patients who had received an allogeneic transplant.
  • One patient suffering from cerebral toxoplasmosis died 9 months post transplant.
  • All other patients were alive at the time of analysis.
  • Our findings suggest that the outcome of allogeneic or syngeneic transplantation in patients with aCML may not be worse than the outcome of transplantation for BCR-ABL-positive CML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Graft vs Host Disease. Humans. Male. Middle Aged. Opportunistic Infections. Remission Induction. Retrospective Studies. Tissue Donors. Transplantation Chimera. Transplantation, Homologous. Transplantation, Isogeneic. Treatment Outcome


19. Topaz O, Polkampally PR, Mohanty PK, Rizk M, Bangs J, Bernardo NL: Excimer laser debulking for percutaneous coronary intervention in left main coronary artery disease. Lasers Med Sci; 2009 Nov;24(6):955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excimer laser debulking for percutaneous coronary intervention in left main coronary artery disease.
  • Excimer laser has been successfully applied to complex atherosclerotic plaques in acute coronary syndromes; however, its role in debulking in left main coronary artery disease has not been fully explored.
  • Details of a series of 20 patients who underwent excimer laser revascularization of a spectrum of left main coronary artery lesions are presented.
  • The left main coronary artery was characterized as protected, semi-protected, poorly protected, or unprotected, depending on the presence or absence of patent bypass grafts to the left anterior descending (LAD) and circumflex (CX) arteries.
  • A fully protected left main coronary artery (LMCA) was present in only 20% of the patients.
  • The target lesions included 11(55%) distal LMCA stenoses, six (30%) ostial stenoses, and one (5%) mid-portion lesions.
  • Two (10%) patients had in-stent re-stenosis of the entire length of the LMCA.
  • Successful LMCA intervention was performed in 19 (95%) patients, while in-hospital complications occurred in only one (5%) patient.
  • Subacute/late stent thrombosis developed 3 months after the procedure in one patient, and two patients died from non-cardiac causes during follow-up.
  • Lesions in LMCAs can be revascularized in selected patients by laser debulking and adjunct stenting.
  • Inadequate protection by bypass grafts and decreased left ventricular function do not contradict utilization of excimer laser.
  • Small laser catheters and high energy levels are required during laser debulking of stenoses of left main coronary arteries.
  • [MeSH-major] Angioplasty, Balloon, Laser-Assisted / methods. Coronary Artery Disease / therapy. Lasers, Excimer / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Angioplasty, Balloon, Coronary / methods. Coronary Angiography. Drug-Eluting Stents. Female. Humans. Male. Middle Aged. Retrospective Studies. Stents. Thrombolytic Therapy

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Laser Med Surg. 2001 Feb;19(1):9-14 [11547819.001]
  • [Cites] Cardiovasc Revasc Med. 2007 Apr-Jun;8(2):84-9 [17574165.001]
  • [Cites] Thromb Haemost. 2001 Oct;86(4):1087-93 [11686328.001]
  • [Cites] Am J Cardiol. 2003 Apr 1;91(7):797-802 [12667563.001]
  • [Cites] Semin Interv Cardiol. 1996 Jun;1(2):135-41 [9552504.001]
  • [Cites] Am J Cardiol. 2008 Jan 15;101(2):169-72 [18178401.001]
  • [Cites] Circulation. 1993 Nov;88(5 Pt 1):2049-57 [8222098.001]
  • [Cites] Catheter Cardiovasc Interv. 2004 Jun;62(2):155-61 [15170703.001]
  • [Cites] Am J Cardiol. 2008 Jan 1;101(1):75-81 [18157969.001]
  • [Cites] J Am Coll Cardiol. 2007 Aug 14;50(7):573-83 [17692740.001]
  • [Cites] Circulation. 2001 Oct 2;104(14 ):1609-14 [11581137.001]
  • [Cites] Lasers Surg Med. 2001;29(2):185-92 [11553909.001]
  • [Cites] Tex Heart Inst J. 2007;34(4):479-84 [18172536.001]
  • [Cites] J Invasive Cardiol. 2004 Apr;16(4):177-80 [15152140.001]
  • [Cites] Lasers Med Sci. 2001;16(2):72-7 [11484757.001]
  • [Cites] Br Heart J. 1993 Mar;69(3):255-9 [8461226.001]
  • [Cites] Cardiology. 1996 Sep-Oct;87(5):384-91 [8894258.001]
  • [Cites] J Thromb Thrombolysis. 2006 Dec;22(3):165-7 [17111201.001]
  • [Cites] J Am Coll Cardiol. 1998 Jan;31(1):37-42 [9426015.001]
  • [Cites] Circulation. 1995 Dec 15;92 (12 ):3408-14 [8521561.001]
  • [Cites] Lasers Med Sci. 1999 Jun;14(2):123-8 [24519167.001]
  • [Cites] Am J Cardiol. 2001 Apr 1;87(7):849-55 [11274939.001]
  • [Cites] J Interv Cardiol. 1995 Dec;8(6):633-8 [10159753.001]
  • [Cites] Am J Cardiol. 2004 Mar 15;93(6):694-701 [15019871.001]
  • [Cites] J Am Coll Cardiol. 2000 May;35(6):1543-50 [10807458.001]
  • [Cites] Cathet Cardiovasc Diagn. 1994 Dec;33(4):317-22 [7889549.001]
  • (PMID = 19238505.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer; 2003 Jun 1;97(11):2760-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
  • BACKGROUND: Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R).
  • c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD).
  • Forty-eight patients with AML (n = 10), MDS (n = 8), myelofibrosis (n = 18), atypical chronic myeloid leukemia (CML; n = 7), chronic myelomonocytic leukemia (CMML; n = 3), or polycythemia vera (n = 2) were treated with imatinib 400 mg daily.
  • One patient with atypical CML had erythroid hematologic improvement.
  • Both patients with polycythemia vera needed fewer phlebotomies (from 2-3 per year to none during the 8 months of therapy and from 3-6 per year to 1 during 9 months of therapy).
  • Treatment was well tolerated.
  • The side effects were similar to those observed in patients with CML.
  • CONCLUSIONS: Within these small subgroups of disease types, single-agent imatinib did not achieve a significant clinical response among patients with AML, MDS, atypical CML, or CMML without PDGF-R fusion genes.
  • Therefore, a combination treatment regimen including imatinib may be more effective.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Myeloproliferative Disorders / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelomonocytic, Chronic / drug therapy. Middle Aged. Polycythemia Vera / drug therapy. Primary Myelofibrosis / drug therapy. Recurrence


21. Park DW, Kim YH, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Kim JJ, Choo SJ, Chung CH, Lee JW, Park SW, Park SJ: Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol; 2010 Oct 19;56(17):1366-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry.
  • OBJECTIVES: This study sought to evaluate the long-term safety and effectiveness of percutaneous coronary intervention (PCI), as compared with coronary artery bypass grafting (CABG), for unprotected left main coronary artery (LMCA) disease.
  • BACKGROUND: Data on the long-term (beyond 5-year) comparative results of treatment of unprotected LMCA disease with stent implantation or CABG are limited.
  • METHODS: We performed a 10-year clinical follow-up of 350 patients with unprotected LMCA disease who underwent PCI with bare-metal stents (BMS) (n = 100) or CABG (n = 250) from January 1995 to April 1999, and 5-year clinical follow-up of 395 patients with unprotected LMCA disease who underwent PCI with drug-eluting stents (DES) (n = 176) or CABG (n = 219) from January 2003 to May 2004.
  • In the 5-year follow-up cohort of DES and concurrent CABG, there was no significant difference in the adjusted risk of death (HR: 0.83; 95% CI: 0.34 to 2.07; p = 0.70) or the risk of the composite outcome (HR: 0.91; 95% CI: 0.45 to 1.83; p = 0.79).
  • The rates of TVR were also higher in the DES group than the CABG group (HR: 6.22; 95% CI: 2.26 to 17.14; p < 0.001).
  • CONCLUSIONS: For the treatment of unprotected LMCA disease, PCI with stent implantation showed similar long-term mortality and rates of death, Q-wave MI, or stroke.
  • However, stenting, even with DES, was associated with higher rates of repeat revascularization than was CABG.
  • [MeSH-major] Coronary Artery Bypass. Coronary Artery Disease / therapy. Stents
  • [MeSH-minor] Coronary Disease / therapy. Drug-Eluting Stents / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myocardial Infarction / mortality. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20946993.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Huang KP, Chase AJ, Cross NC, Reiter A, Li TY, Wang TF, Chu SC, Lu XY, Li CC, Kao RH: Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia. Int J Hematol; 2008 Sep;88(2):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.
  • Most of them are atypical chronic myeloid leukemia (CML) or other myeloproliferative disorders (MPD), and are predominantly in the male.
  • We report a female patient with acute myeloid leukemia (AML) initially presenting with normal karyotype and negative HLA-DR expression who achieved complete remission after standard chemotherapy.
  • The disease relapsed 7 months later with cytogenetic change of t(8;9)(p22;p24).
  • Flow cytometry analysis showed evolutional change of immunophenotype from negative to positive HLA-DR expression and fluorescence in situ hybridization (FISH) analysis demonstrated a PCM1-JAK2 fusion gene.
  • [MeSH-major] Autoantigens / genetics. Cell Cycle Proteins / genetics. HLA-DR Antigens / genetics. Janus Kinase 2 / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Chromosome Aberrations. Chromosomes, Human, Pair 8. Chromosomes, Human, Pair 9. Fatal Outcome. Female. Flow Cytometry. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Jun;9(6):972-6 [7596187.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2084-91 [12357361.001]
  • [Cites] Scand J Immunol. 1997 Oct;46(4):379-87 [9350289.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] J Immunol. 1996 Aug 15;157(4):1559-68 [8759739.001]
  • [Cites] Jpn J Ophthalmol. 2001 Jan-Feb;45(1):13-21 [11163041.001]
  • [Cites] J Cell Physiol. 1997 Oct;173(1):110-4 [9326455.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2260-9 [11160280.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2662-7 [15805263.001]
  • [Cites] Clin Lab Haematol. 2001 Jun;23(3):173-9 [11553058.001]
  • [Cites] Leukemia. 1998 Sep;12 Suppl 1:S7-12 [9777887.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1692-6 [16034466.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Blood. 1999 Jul 15;94(2):694-700 [10397736.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2535-40 [9326218.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1161-7 [2122794.001]
  • [Cites] Leuk Lymphoma. 1994 Jan;12(3-4):211-22 [7909466.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Crit Rev Immunol. 1993;13(3-4):247-68 [8110378.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1148-51 [16226118.001]
  • [Cites] Leukemia. 2006 Mar;20(3):536-7 [16424865.001]
  • [Cites] Leukemia. 1995 May;9(5):875-8 [7769851.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] J Clin Invest. 1985 Oct;76(4):1391-7 [2414320.001]
  • [Cites] Oncogene. 2005 Nov 3;24(48):7248-52 [16091753.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):17-31 [9045301.001]
  • (PMID = 18594780.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Cell Cycle Proteins; 0 / HLA-DR Antigens; 0 / Oncogene Proteins, Fusion; 0 / PCM1 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


23. Dubois C, Dens J, Sinnaeve P, Belmans A, Van Cleemput J, Mendez M, Piessens J, Desmet W: Results of percutaneous coronary intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting. Am J Cardiol; 2008 Jan 1;101(1):75-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of percutaneous coronary intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting.
  • Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery (LMCA) is controversial.
  • In 143 patients who underwent PCI of the unprotected LMCA, 30-day mortality was compared with predicted cumulative risk-adjusted perioperative surgical mortality based on logistic European System for Cardiac Operative Risk Evaluation.
  • The overall major adverse cardiac event rate at 1 year was 34.3%, reflecting the high-risk profile of the patient population.
  • Angiographic follow-up in 90 of the 118 patients alive at 6 months showed binary restenosis of 6% in patients treated with drug-eluting stents versus 29% in patients receiving bare-metal stents (p < or =0.01).
  • In conclusion, PCI for unprotected LMCA disease was associated with acceptable short- and medium-term outcomes in patients at low to intermediate risk of bypass surgery.
  • However, in selected indications, PCI of the LMCA can offer an alternative to surgery, especially when using drug-eluting stents.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Artery Disease / mortality. Coronary Artery Disease / therapy
  • [MeSH-minor] Acute Coronary Syndrome / therapy. Aged. Aged, 80 and over. Coronary Restenosis / epidemiology. Female. Humans. Male. Myocardial Infarction / epidemiology. Outcome Assessment (Health Care). Retreatment. Risk Adjustment. Sirolimus / administration & dosage. Sirolimus / analogs & derivatives. Stents

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157969.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biolimus A9; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


24. Yan Z, Yang B, Wang QS, Wang LL, Han XP, Ren F, Yu L: [Clinical pathological features of the 8p11 myeloproliferative syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was aimed to investigate the clinico-pathological features, diagnosis and treatment of the 8p11 (eight p11) myeloproliferative syndrome (EMS).
  • Karyotypes were determined by conventional cytogenetic method, and bcr/abl fusion gene was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • The results indicated that EMS was a relatively rare disease characterized by the occurrence of a bcr/abl-negative myeloproliferative disorder and a T-cell lymphoblastic lymphoma (T-LBL).
  • Bone marrow examination showed myeloid hyperplasia or myeloproliferative neoplasm, often accompanied by eosinophilia.
  • Flow cytometric immunophenotyping showed increased myelomonoblasts; cytogenetic analysis showed a translocation at the 8p11 locus; RT-PCR demonstrated non bcr/abl fusion gene.
  • At the molecular level, all cases carried a chromosomal abnormality involving the fibroblast growth factor receptor 1 (FGFR1) at chromosome 8p11.
  • The most common partner is ZNF198 on chromosome 13q11-12.
  • Majority of patients terminate in acute myeloid leukemia which is resistant to conventional chemotherapy.
  • In conclusion, EMS is myeloid and lymphoid neoplasm, associates with FGFR1 rearrangements.
  • It is usually misdiagnosed as T-LBL, atypical chronic myeloid leukemia (aCML) or chronic myelogenous-monocytic leukemia (CMML).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129285.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  •  go-up   go-down


25. Park SJ, Kim YH: Percutaneous coronary intervention as an alternative to bypass surgery for unprotected LMCA stenosis. Expert Rev Cardiovasc Ther; 2008 Sep;6(8):1107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous coronary intervention as an alternative to bypass surgery for unprotected LMCA stenosis.
  • Hemodynamically significant left main coronary artery (LMCA) stenosis is found in approximately 4% of diagnostic coronary angiograms and is known as unprotected LMCA stenosis if the left coronary artery and left circumflex artery have no patent previous grafts.
  • Previous randomized studies have demonstrated a significant reduction in mortality when revascularization by coronary artery bypass graft (CABG) surgery was undertaken compared with medical treatment.
  • However, with the advent of drug-eluting stents (DES), the long-term outcomes of PCI with DES to treat unprotected LMCA stenoses have been reported to be acceptable.
  • Therefore, apart from the current guidelines, PCI for unprotected LMCA stenosis in many countries is often undertaken in individuals who are at very high risk of CABG or refuse to undergo a sternotomy.
  • Future randomized studies comparing CABG versus PCI using DES for treatment of unprotected LMCA stenosis would be a great advance in the clinical knowledge of adopting appropriate treatments.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Stenosis / therapy. Stents
  • [MeSH-minor] Coronary Restenosis / epidemiology. Coronary Restenosis / prevention & control. Drug-Eluting Stents. Humans. Platelet Aggregation Inhibitors / therapeutic use. Randomized Controlled Trials as Topic. Registries. Treatment Outcome. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793113.001).
  • [ISSN] 1744-8344
  • [Journal-full-title] Expert review of cardiovascular therapy
  • [ISO-abbreviation] Expert Rev Cardiovasc Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors
  • [Number-of-references] 39
  •  go-up   go-down






Advertisement